Informations:
Erreur:
ID
33110
Description
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B
Mots-clés
Versions (1)
- 28/11/2018 28/11/2018 -
Détendeur de droits
GSK group of companies
Téléchargé le
28 novembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021
Visit 1: Eligibility Form
- StudyEvent: ODM
Similar models
Visit 1: Eligibility Form
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Date of Visit
Item
Date of Visit
date
Subject Number
Item
Subject Number
integer
Item
Did the subject meet all the entry criteria?
integer
CL Item
Yes (1)
CL Item
No (tick all boxes corresponding to violations of any inclusion/exclusion criteria below) (2)
Tick "No" for any inclusion criteria subject failed
Item
Tick "No" for any inclusion criteria subject failed
text
1.Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
Item
1.Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
boolean
2.Administration of one dose of hepatitis B vaccine at birth (within 72 hours after birth)
Item
2.Administration of one dose of hepatitis B vaccine at birth (within 72 hours after birth)
boolean
3.A male or female between, and including, 11 and 17 weeks of age at the time of the first DTPw vaccination.
Item
3.A male or female between, and including, 11 and 17 weeks of age at the time of the first DTPw vaccination.
boolean
4.Written informed consent obtained from parent or guardian of the subject.
Item
4.Written informed consent obtained from parent or guardian of the subject.
boolean
5.Free of obvious health problems as established by medical history and clinical examination before entering into the study.
Item
5.Free of obvious health problems as established by medical history and clinical examination before entering into the study.
boolean
6.Born after a normal gestation period (36 to 42 weeks).
Item
6.Born after a normal gestation period (36 to 42 weeks).
boolean
Tick "Yes" for any of the exclusion criteria that disqualified the subject from entry
Item
Tick "Yes" for any of the exclusion criteria that disqualified the subject from entry
text
7.Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Item
7.Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
boolean
8.Chronic administration (>14 days) of immunosuppressants or other immune-modifying drugs since birth.
Item
8.Chronic administration (>14 days) of immunosuppressants or other immune-modifying drugs since birth.
boolean
9.Planned administration/Administration of vaccine not foreseen by the study protocol within 30 days before the first vaccine dose or planned administration during the study period with the exeption of oral polio vaccine (OPV).
Item
9.Planned administration/Administration of vaccine not foreseen by the study protocol within 30 days before the first vaccine dose or planned administration during the study period with the exeption of oral polio vaccine (OPV).
boolean
10.Bacille-Calmette-Guérin (BCG) vaccine received after the first 6 weeks of life.
Item
10.Bacille-Calmette-Guérin (BCG) vaccine received after the first 6 weeks of life.
boolean
11. Previous vaccination against diphtheria, tetanus, and/or pertussis.
Item
11. Previous vaccination against diphtheria, tetanus, and/or pertussis.
boolean
12.History of diphtheris, tetanus, pertussis and/or hepatitis B disease.
Item
12.History of diphtheris, tetanus, pertussis and/or hepatitis B disease.
boolean
13.Known exposure to diphtheria, tetanus, pertussis and/or hepatitis B disease since birth.
Item
13.Known exposure to diphtheria, tetanus, pertussis and/or hepatitis B disease since birth.
boolean
14.Gastroenteritis within 7 days preceeding the first study vaccine administration.
Item
14.Gastroenteritis within 7 days preceeding the first study vaccine administration.
boolean
15.Any confirmed or suspected immunosuppresive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
Item
15.Any confirmed or suspected immunosuppresive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).
boolean
16.A family history of congenital or hereditary immunodeficiency.
Item
16.A family history of congenital or hereditary immunodeficiency.
boolean
17.History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
Item
17.History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
boolean
18.Major congenital defects or serious chronic illness.
Item
18.Major congenital defects or serious chronic illness.
boolean
19.History of any neurologic disorders or seizures
Item
19.History of any neurologic disorders or seizures
boolean
20.Acute disease at the time of enrollment.
Item
20.Acute disease at the time of enrollment.
boolean
21.Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Item
21.Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
boolean
22.Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
Item
22.Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
boolean
Record treatment number
Item
Record treatment number
integer